Author:
Schrijvers Dirk,Van Erps Peter,Cortvriend Jim
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference60 articles.
1. Mathers C, Boschi-Pinto C, Lopez A. Murray C. Cancer incidence, mortality and survival by site for 14 regions of the world. Available at: www.who.int/healthinfo/paper13.pdf. Accessed May 21, 2010.
2. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–1490.
3. Schrijvers D. Androgen-independent prostate cancer. Recent Results Cancer Res. 2007;175:239–249.
4. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764.
5. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008;19:1749–1753.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献